Literature DB >> 23873630

The physical stability of the recombinant tuberculosis fusion antigens h1 and h56.

Mette Hamborg1, Ryan Kramer, Carole E Schanté, Else Marie Agger, Dennis Christensen, Lene Jorgensen, Camilla Foged, C Russell Middaugh.   

Abstract

The recombinant fusion proteins hybrid 1 [H1 (Ag85B-ESAT-6)] and hybrid 56 [H56 (Ag85B-ESAT-6-Rv2660c)] derived from Mycobacterium tuberculosis are promising antigens for subunit vaccines against tuberculosis. Both antigens are early batches of antigens to be enrolled in human clinical trials and it is therefore important to characterize their conformational stability in solution as well as upon interaction with adjuvants. In this study, the physical stability of the two antigens was characterized using a number of biophysical techniques. Dynamic light scattering and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analyses demonstrated that both antigens exist as a distribution of multimeric states under nonstressed conditions. Their conformational stability was monitored as a function of pH and temperature and visualized in three-index empirical phase diagrams. Both antigens showed a gradual loss of secondary as well as tertiary structure as a function of temperature, with no cooperative transitions observed. Preformulation studies with the Th1-inducing cationic adjuvant CAF01 showed that the antigens were almost completely surface adsorbed. Upon adsorption, the liposome size increased; however, the physical stabilities of the bound and the unbound antigens were comparable. This study provides important information about the biophysical properties of H1 and H56 and highlights the analytical challenges of characterizing complex vaccine formulations.
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  biopharmaceutical characterization; fluorescence spectroscopy; liposome; vaccine adjuvants; vaccine delivery

Mesh:

Substances:

Year:  2013        PMID: 23873630     DOI: 10.1002/jps.23669

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant.

Authors:  Grant E Frahm; Alex W T Pochopsky; Tessa M Clarke; Michael J W Johnston
Journal:  PLoS One       Date:  2016-02-29       Impact factor: 3.240

2.  Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.

Authors:  Aneesh Thakur; Cristina Rodríguez-Rodríguez; Katayoun Saatchi; Fabrice Rose; Tullio Esposito; Zeynab Nosrati; Peter Andersen; Dennis Christensen; Urs O Häfeli; Camilla Foged
Journal:  Front Immunol       Date:  2018-11-30       Impact factor: 7.561

3.  Single-dose Ag85B-ESAT6-loaded poly(lactic-co-glycolic acid) nanoparticles confer protective immunity against tuberculosis.

Authors:  Anshu Malik; Manish Gupta; Rajesh Mani; Rakesh Bhatnagar
Journal:  Int J Nanomedicine       Date:  2019-05-01

Review 4.  Platform technologies for modern vaccine manufacturing.

Authors:  Hayley K Charlton Hume; Linda H L Lua
Journal:  Vaccine       Date:  2017-03-25       Impact factor: 3.641

Review 5.  Engineering DNA vaccines against infectious diseases.

Authors:  Jihui Lee; Shreedevi Arun Kumar; Yong Yu Jhan; Corey J Bishop
Journal:  Acta Biomater       Date:  2018-08-31       Impact factor: 8.947

6.  Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.

Authors:  Tetyana Dashivets; Jan Stracke; Stefan Dengl; Alexander Knaupp; Jan Pollmann; Johannes Buchner; Tilman Schlothauer
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.